2. Search Result
Search Result
Results for "

KMT9

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Recombinant Proteins

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-157486
    KMI169

    		Epigenetic Reader Domain Cancer
    KMI169 is a potent and selective inhibitor targeting lysine methyl-transferase (KMT9) (IC50 = 0.05 μM, Kd = 0.025 μM). KMI169 functions as a bi-substrate inhibitor targeting the cofactor S-5’-adenosyl-L-methionine (SAM) and substrate binding pockets of KMT9. KMI169 can downregulate target genes involved in cell cycle regulation and impair proliferation of tumor cells by inhibiting KMT9. KMI169 is a valuable tool to probe cellular KMT9 functions and can be research for combating diseases including prostate, lung, colon, and invasive bladder cancer .
    KMI169
  • HY-174450
    KMT9-IN-1

    		Epigenetic Reader Domain Cancer
    KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and the ethyl ester prodrug of compound 7b. KMT9-IN-1 releases the active form 7b via esterases in cells. KMT9-IN-1 targets KMT9 in cells and reduces H4K12me1 levels. KMT9-IN-1 has antitumor activity against colon cancer. KMT9-IN-1 can be used in the research of prostate cancer and hepatocellular carcinoma .
    KMT9-IN-1
  • HY-174451
    KMT9-IN-2

    		Epigenetic Reader Domain Cancer
    KMT9-IN-2 (Compound 7b) is an active form of a KMT9 inhibitor (Kd of 10 nM). KMT9-IN-2 can be used in the research of colon cancer .
    KMT9-IN-2
  • HY-RS08984
    N6AMT1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    N6AMT1 Human Pre-designed siRNA Set A contains three designed siRNAs for N6AMT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    N6AMT1 Human Pre-designed siRNA Set A
    N6AMT1 Human Pre-designed siRNA Set A
  • HY-183602
    FRC-303

    		DNA/RNA Synthesis Cancer
    FRC-303 is a CHD1 inhibitor with a Kd of 0.14 μM and an IC50 of 0.18 μM. FRC-303 binds to the H3K4me3 binding site of CHD1 tandem chromodomain, forms aromatic cage interactions and extended ligand contacts, acts as a methyl-lysine mimic, and occupies natural peptide ligand-binding regions. FRC-303 can be used for the research of prostate cancer .
    FRC-303
  • HY-183603
    FRC-222

    		DNA/RNA Synthesis Cancer
    FRC-222 is a CHD1 tandem chromodomain inhibitor with a Kd of 0.15 μM and an IC50 of 0.18 μM. FRC-222 binds to the H3K4me3 binding site of CHD1 tandem chromodomain via aromatic cage interactions and extended ligand contacts. FRC-222 can be used for the research of prostate cancer[1].
    FRC-222

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: